{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:57:11Z","timestamp":1782953831370,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["2023\/ABM\/01\/00015-00"],"award-info":[{"award-number":["2023\/ABM\/01\/00015-00"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09062-8","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T06:47:45Z","timestamp":1756709265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-3821","authenticated-orcid":false,"given":"Marta","family":"Ostrowska-Le\u015bko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"M\u0105dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Bobi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"4","key":"9062_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040849","volume":"13","author":"A \u0141ukomska","year":"2021","unstructured":"\u0141ukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasi\u00f3wka M, et al. Recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish patients with ovarian cancer. Cancers (Basel). 2021;13(4): 849.","journal-title":"Cancers (Basel)"},{"key":"9062_CR2","doi-asserted-by":"crossref","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.\u00a0Front Cell Dev.Biol. 2020;8.\u00a0 https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.564601.","DOI":"10.3389\/fcell.2020.564601"},{"issue":"1","key":"9062_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015Oct 1;139(1):10\u20136.","journal-title":"Gynecol Oncol"},{"issue":"9990","key":"9062_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015Jul 18;386(9990):249\u201357.","journal-title":"The Lancet"},{"issue":"12","key":"9062_CR5","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018Dec;19(12):1680\u20137.","journal-title":"Lancet Oncol"},{"key":"9062_CR6","unstructured":"Leczenie chirurgiczne raka jajnika \u2013 Rekomendacje ESGO. Polskie Towarzystwo Ginekologii Onkologicznej. [cited 2023 Apr 16].\u00a0https:\/\/ptgo.pl\/rekomendacje\/leczenie-chirurgiczne-raka-jajnika-rekomendacje-esgo\/."},{"issue":"26","key":"9062_CR7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. JCO. 2019;37(26):2317\u201328.","journal-title":"JCO"},{"issue":"26","key":"9062_CR8","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of Bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"9062_CR9","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018Dec 27;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"9062_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019Dec 19;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"9062_CR11","doi-asserted-by":"crossref","unstructured":"Gonzalez-Molina J, Moyano-Galceran L, Single A, Gultekin O, Alsalhi S, Lehti K. Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance.\u00a0Semin Cancer Biol. 2022. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1044579X22000682.","DOI":"10.1016\/j.semcancer.2022.03.012"},{"key":"9062_CR12","doi-asserted-by":"crossref","unstructured":"Yin R, Li N, Wu L, Wang J, Zhu J, Pan L, et al. Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy. JCO. 2022;40(16_suppl):5551\u20135551.","DOI":"10.1200\/JCO.2022.40.16_suppl.5551"},{"issue":"12","key":"9062_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727102","volume":"17","author":"CH Zhou","year":"2021","unstructured":"Zhou CH, Yang F, Jiang WJ, Zhang YC, Yang HY, Zeng L, et al. Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. Front Pharmacol. 2021Nov;17(12): 727102.","journal-title":"Front Pharmacol"},{"issue":"346","key":"9062_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"9","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013Jan;9(346): e7586.","journal-title":"BMJ"},{"issue":"20","key":"9062_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013Nov 27;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"9062_CR16","unstructured":"G M, R K, M B, M B, G G, A J, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J\u00a0Hypertens\u00a02023;41(12).\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/37345492\/."},{"key":"9062_CR17","unstructured":"Ra B, X R, Jj C, E B, C B, A C. ESC Guidelines for the management of acute coronary syndromes.\u00a0Eur Heart J. 2023;44(38). https:\/\/pubmed.ncbi.nlm.nih.gov\/37622654\/."},{"issue":"3","key":"9062_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","volume":"26","author":"RB Rutherford","year":"1997","unstructured":"Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517\u201338.","journal-title":"J Vasc Surg"},{"key":"9062_CR19","doi-asserted-by":"crossref","unstructured":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart. JAMA. 1940;114(20):2054.","DOI":"10.1001\/jama.1940.02810200082036"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09062-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09062-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09062-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:15:21Z","timestamp":1757466921000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09062-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9062"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09062-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6470587\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial has been prospectively registered at the EUCT number: 2023\u2013509659-15\u201300, 15\/07\/2024. The trial protocol has been reviewed by the European Medicines Agency (Reference number: 2023\u2013509659-15\u201300, 15\/07\/2024). In compliance with the Declaration of Helsinki of 1964, as revised in 2013, the International Conference of Harmonization Guidelines for Good Clinical Practice, and the guidelines of local ethics committees, written informed permission will be obtained by investigators from all subjects when patients are enrolled in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Marta Ostrowska-Lesko: Clinical trials: CELLTRION INC. Stocks and shares: M2 Innovations, EBMed.Marcin Bobinski: Clinical trials: Astra Zeneca, MSD, Aeterna Zentalis, Clovis, Corcept Therapeutics; Lectures and Grants: GSK, Astra Zeneca, Abbvie; Stocks and shares: M2 Innovations, Ryvu Therapeutics, PolTreg, ScopeFluidics.Radoslaw Madry: Lecturer: Abbvie, Amgen; AstraZeneca; GSK; Roche; MSD; Medisson. Research for: Amgen, Antisoma, AstraZeneca, Bayer, GSK, Glycotope GmbH, Janssen, Menarini, Morphotek, MSD, OSI Pharmaceuticals, PharmaMar, Roche, Sanofi, Sotio, Tesaro. Consultancy for: AstraZeneca, GSK, MSD, Pharma@, Roche.This study was not funded or supported by the above partners, and the author did not receive any financial benefits related to this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}